WHEN IT’S TIME FOR
FIRST-LINE CLL
TREATMENT
Indication
GAZYVA® (obinutuzumab), in combination with chlorambucil, is indicated for the treatment of patients with
previously untreated chronic lymphocytic leukemia (CLL).
Boxed WARNINGS: HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL
LEUKOENCEPHALOPATHY
• Hepatitis B Virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure,
and death, can occur in patients receiving CD20-directed cytolytic antibodies, including GAZYVA.
Screen all patients for HBV infection before treatment initiation. Monitor HBV positive patients
during and after treatment with GAZYVA. Discontinue GAZYVA and concomitant medications in
the event of HBV reactivation
• Progressive Multifocal Leukoencephalopathy (PML) including fatal PML, can occur in patients
receiving GAZYVA
Please see the following pages for additional Important Safety Information
and brief summary of full Prescribing Information, including Boxed WARNINGS.